Principal Financial Group Inc. Has $43,000 Stock Holdings in Savara Inc (NASDAQ:SVRA)

Principal Financial Group Inc. trimmed its position in Savara Inc (NASDAQ:SVRA) by 42.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,188 shares of the company’s stock after selling 7,607 shares during the quarter. Principal Financial Group Inc.’s holdings in Savara were worth $43,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. ProShare Advisors LLC lifted its holdings in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after acquiring an additional 2,114 shares during the last quarter. Vanguard Group Inc. grew its holdings in Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after acquiring an additional 148,673 shares during the last quarter. CANADA LIFE ASSURANCE Co bought a new position in Savara during the 1st quarter worth $35,000. Price T Rowe Associates Inc. MD grew its position in shares of Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after buying an additional 4,625 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after acquiring an additional 746,407 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Trading Up 1.5 %

Savara stock opened at $3.46 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market capitalization of $593.81 million, a PE ratio of -8.05 and a beta of 1.02. The business’s fifty day moving average is $3.73 and its 200 day moving average is $4.10. Savara Inc has a one year low of $2.82 and a one year high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). On average, sell-side analysts predict that Savara Inc will post -0.45 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on SVRA. JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, HC Wainwright reduced their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.17.

Insider Activity at Savara

In other news, Director Joseph S. Mccracken bought 20,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.13% of the stock is owned by company insiders.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.